C3G

CAMBRIDGE, Mass. — September 17, 2026 Biogen announced publication of prespecified adolescent subgroup results from the Phase 3 VALIANT...

FREIBURG, Germany — September 15, 2026 One04 Therapeutics GmbH & Co. KG announced its launch as a clinical-stage biopharmaceutical...

CAMBRIDGE, Mass., June 3, 2026 Biogen Inc. announced that 14 abstracts from its expanding nephrology portfolio have been accepted...

HOUSTON, Texas | April 10, 2026 FibroBiologics has unveiled promising preclinical data for its novel thymus organoid platform, demonstrating...

WALTHAM, Massachusetts | April 9, 2026 Swedish Orphan Biovitrum (Sobi) has announced that Health Canada has approved EMPAVELI® (pegcetacoplan),...

Bagsværd, Denmark & Seattle, USA – October 15, 2025 – In a move strengthening its foothold in immunology and...

BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...